Conferences - Day 1

The Connect in Pharma conferences deliver high quality content designed in collaboration with world-leading organisations.

Morning session: post-covid: the future for European pharma production

Morning session: POST-COVID: THE FUTURE FOR EUROPEAN PHARMA PRODUCTION

09:45 - 09:55

Introduction

 

Thierry Lhuillier, Industrial Performance and Operational Efficiency Director, UPSA

CHAIR

10:00 - 10:30

The European pharmaceutical industry facing the challenges of health dependency: constraints and opportunities

Even on a budgetary scale, improving health security is more than just adjusting economic variables. As a result of such an ambition, health-related industrial policies must involve new trade-offs at several levels.

A new challenge in public policy faces us. In the race to develop vaccines, European countries have been constrained by two trends: 1) the fragility of their positions in a globalized industry and 2) the inability to position themselves on biotechnology opportunities. 

Marie Coris,  Researcher in economics at University of Bordeaux

10:35 - 11:05

Establishing a strong and competitive industry in Europe: what does that mean – Upsa in Agen as a showcase

 • Recent crisis as an accelerator

•  A multistep approach to compete in a European site

• Local anchoring : a responsibility

• Economics and regulation – Orientation and perspective for strengthening the competitiveness and sustainability of European sites.

Thierry Lhuillier, Industrial Performance and Operational Efficiency Director, UPSA

CHAIR

11:20 - 11:50

Relocation of the production of pharmaceuticals: A strategic endeavour for the European Union

Many governmental and political leaders have reacted by requiring the relocation of pharmaceutical production in Europe since January 2020. The purpose of this presentation is to explore how supply chains are structured, to what extend production could be repatriated into Europe and what are the roadblocks to such endeavour.

Jean-François Hilaire, Executive Committee Member, Head of Business Unit Advanced Delivery Systems, Recipharm

11:55- 12:25

Euroject® Innovation in Injectables

During the Covid-19 pandemic, many governments sought a health sovereignty tool to provide a sufficient number of vaccine doses for their population. By developing Euroject, a ready-to-use single-dose injection system that is open and free of intellectual property, Unither Pharmaceutical is offering a solution under full European control with numerous advantages for European patients in terms of deployment capacity, cost and implementation by healthcare staff. 

Eric Goupil , CEO, Unither Pharmaceuticals

CHAIR

12:25 - 12:45

Q&A session

After the four morning sessions, you will have the opportunity to get involved in a Q&A session.

By getting involved in the Q&A session, you will have your curiosity quenched on the hot topics you have seen in the morning sessions.

Afternoon session: developing innovative packaging solutions

Morning session: POST-COVID: THE FUTURE FOR EUROPEAN PHARMA PRODUCTION

14:00 - 14:15

Introduction

 

Tiffany McIntire, Principal Human Factors Engineer, Roche

CHAIR

14:15 - 14:45

Patient-focused drug-delivery solutions for subcutaneous injection of large molecule biologics

A patient-focused approach is implemented to address subcutaneous administration of large volumes of large-molecule biologics. Furthermore, Patient Preference Information (PPI) is studied both from the regulatory aspect and from the results of two existing clinical studies. In order to address the patient and user needs, we need to focus on SC administration and current landscape of drug delivery solutions for large molecules biologics.

Dr. Reza Abedian, Senior Medical Affairs Manager, Gerresheimer

 

14:50- 15:20

How to better control the unknown factors of innovative developments and accelerate them

The organization must control project progress if it wants to accelerate projects. The presentation will cover the major challenges (materials/regulations, customer requirements, design/use, and process/industrialization). 

• The different means to anticipate failures 

• Partnership – simulation. It is a process or is it functional?

• Modelling – prototyping 

Isabelle Constant, Research & Development Director at Technoflex 

CHAIR

15:35 - 16:05

Developing patient-centric packaging solutions

• How to identify projects in your pharmaceutical pipeline that would benefit from HF expert review and testing

• Examples of packaging solutions developed following the Human Factors process

• A review of regulations in order to adhere to best practices

Tiffany McIntire, Principal Human Factors Engineer, Roche

 
 

16:10- 16:40

Selecting drug delivery systems for higher dose and higher volume

The organization must control project progress if it wants to accelerate projects. The presentation will cover the major challenges (materials/regulations, customer requirements, design/use, and process/industrialization). 

• The different means to anticipate failures 

• Partnership – simulation. It is a process or is it functional?

• Modelling – prototyping 

Vincent Laperle, Techhnical Services Specialist at BD 

CHAIR

16:40 - 17:00

Q&A session

After the four morning sessions, you will have the opportunity to get involved in a Q&A session.

By getting involved in the Q&A session, you will have your curiosity quenched on the hot topics you have seen in the afternoon sessions.

Explore the complete list of sessions and workshops

Conferences day 2

Conference programme day 2

Explore the full list of speakers and sessions for day 2
find out more

Workshops day 1

Workshops day 1

Explore the complete list of interactive workshops for day 1
find out more

Workshops day 2

Workshops day 2

Explore the complete list of interactive workshops for day 2
FIND OUT MORE